Document:

Letter agreement

 Exhibit 10.39 
  
 September 27, 2005 
  
 VIA HAND DELIVERY 
  

Frank Litvack, M.D. 
 Conor Medsystems, Inc. 
  

	Re:	  New Employment Terms 

  
 Dear Frank: 
  
 As we discussed, this letter (the “Agreement”) sets forth the new terms and conditions of your employment relationship with Conor Medsystems, Inc. (the
“Company”). On September 27, 2005, these terms and conditions were approved by the Company’s Compensation Committee (“Committee”) of the Board of Directors (“Board”). Except as expressly stated herein, this
Agreement supersedes and replaces all previous agreements between you and the Company, including but not limited to the Engagement Letter dated January 1, 2002, your Contract Extension dated August 7, 2003 and your letter agreement dated
March 4, 2005. As noted below, your current stock option grants are not affected by this Agreement. The terms contained in this Agreement will become effective as of the date that both you and the Company sign this Agreement (the
“Effective Date”). 
  
 1. Position and
Reporting Relationship 
  
 You will continue to be employed in the full-time
employment position of Chief Executive Officer (“CEO”) reporting to the Company’s Board. 
  
 2. Base Salary 
  
 Effective September 27, 2005, you will have a base salary at an annualized rate of $350,000, less standard payroll deductions and withholdings, and paid in
accordance with the Company’s normal payroll schedule. You will be considered for annual increases in base salary in accordance with Company policy and subject to review and approval by the Committee. 
  
 3. Annual Target Bonus 
  
 For calendar year 2005, you shall also be eligible to earn an annual target bonus pursuant
to the Company’s 2005 Bonus Plan. The bonus, if awarded, shall be subject to applicable payroll withholdings and employment taxes. The Committee will determine, in its sole discretion, whether and to what extent the bonus has been earned. You
will be considered for annual target bonuses in accordance with Company policy and subject to review and approval by the Committee. 
  
 4. Option Grants 
  
 Your current stock options are not affected by this Agreement, and your current stock option agreements will remain in full force and effect in accordance with their
terms. As approved by the Committee on September 27, 2005, the Company granted you an option under the Company’s 2004 Equity Incentive Plan (the “Plan”) to purchase two hundred and seventy-five thousand (275,000) shares of
the Company’s Common Stock (the “New Option”) at the fair market value on the date of grant. The New Option shall contain a vesting schedule, contingent upon your continued service to the Company as an employee, pursuant to which the
shares shall vest in equal monthly installments over four (4) years. The New Option 

 will be governed in full by the terms and conditions of the Plan, a stock option grant notice, stock option agreement and
the Chief Executive Officer Change of Control Severance Agreement (the “CEO Agreement”). 
  
 5. Employee Benefits; Business Expenses 
  
 You will continue to be eligible to participate in the Company’s standard employee benefit plans, pursuant to the terms, conditions and limitations of the benefit
plans. In addition, you will continue to be eligible for reimbursement of your reasonable business expenses incurred in connection with your employment, including but not limited to reasonable lodging and travel expenses, in accordance with the
Company’s business expense reimbursement policies and practices. 
  
 6. Confidentiality Agreement; Compliance With Company Policies 
  
 The Confidentiality, Invention Assignment and Nonsolicitation Agreement that you signed on May 15, 2002 (the “Confidentiality Agreement”) is not affected by this Agreement and will remain in full force
and effect in accordance with its terms. You will continue to be required to abide by the Confidentiality Agreement as a condition of your employment. In addition, you will continue to be required to abide by the Company’s policies and
procedures, as may be in effect from time to time. 
  
 7. Outside Activities 
  
 You will continue to be prohibited from
engaging in any other employment, occupation, consulting or other business activity directly related to the business in which the Company is now involved or becomes involved during the term of your employment, nor will you engage in any other
activities that conflict with your obligations to the Company. Similarly, you agree to continue to not bring any third-party confidential information to the Company, including but not limited to that of your former employer or other current
employers, and that in performing your duties for the Company you will not in any way utilize or disclose any such information. The Company acknowledges that you are a practicing interventional cardiologist on a part-time basis at Cedars Sinai
Medical Center and that you may continue to perform services in that capacity. The Company further acknowledges that you are rendering services and may continue to render services to other entities engaged in the medical device business in
connection with interventional cardiology, including, without limitation, Savacor, Inc., Immusol, Inc., and Corset, Inc. and that you may have an equity position in such entities. The Company consents to you continuing to render such services and
holding any equity position that you may have, or that may result from the exercise of stock options, in such entities; provided, however, that your confidentiality and other obligations to the Company will apply to the providing of such services.

  
 8. At-Will Employment Relationship

  
 Your employment relationship is terminable at-will, and either you or the
Company may terminate your employment relationship at any time. 
  
 9. Severance and Change of Control Arrangements 
  
 Severance and change of control arrangements will be governed by the CEO Agreement in the form approved by the Board. Pursuant to its terms and conditions, the CEO Agreement provides for accelerated vesting of option shares in the event you
are either terminated without Cause or Constructively Terminated. 

 10. Miscellaneous 
  
 This Agreement, together with your Confidentiality Agreement, CEO Agreement and stock option agreements, sets forth and forms the complete
and exclusive statement of your agreement with the Company concerning the terms and conditions of your employment as of the Effective Date. This Agreement supersedes any other agreements or promises made to you by anyone, whether oral or written,
concerning the subject matters set forth herein including, but not limited to, your Engagement Letter dated January 1, 2002, your Contract Extension dated August 7, 2003 and your letter agreement dated March 4, 2004. Changes in your
employment terms, other than those changes expressly reserved to the Company’s, Committee’s or Board’s discretion in this Agreement, require a written modification signed by a duly authorized officer of the Company which must be
approved by the Committee. This Agreement may be executed in separate counterparts, any one of which need not contain signatures of more than one party, but all of which taken together shall constitute one and the same Agreement, and signatures
transmitted via facsimile shall be deemed the equivalent of originals. 
  
 We look
forward to continuing your employment relationship under the terms and conditions contained herein. To accept this Agreement, please sign and return this letter to the Company. 
  

			
	Sincerely,	 	 
	CONOR MEDSYSTEMS, INC.	 	 
		
	 /s/ George M. Milne

	 	 /s/ Michael Boennighausen

	George M. Milne, Jr., Ph.D.	 	Michael Boennighausen
	Compensation Committee	 	Chief Financial Officer
	Board of Directors	 	 

  

	
	Accepted:
	
	 /s/ Frank Litvack

	Frank Litvack, M.D.Chief Executive Change of Control and Severance Agreement

 Exhibit 10.40 
  
 CHIEF EXECUTIVE CHANGE OF CONTROL AND SEVERANCE AGREEMENT 
  
 This Chief Executive Officer Change of Control and Severance Agreement (the
“Agreement”) is made and entered into as of September 27, 2005, by and between Conor Medsystems, Inc., a Delaware corporation (the “Company”), and Frank Litvack, M.D. (the
“Executive”). 
  
 WHEREAS, the Company’s Board of Directors (the “Board”) has determined that it would be in the best interests of the Company and its stockholders to provide for certain severance benefits
in the event the Executive’s employment is terminated in order to align further the interests of the Executive with those of the stockholders of the Company; 
  
 NOW, THEREFORE, in consideration of the Executive’s continued employment with the
Company, the Company and the Executive hereby agree as follows: 
  
 1.
DEFINITIONS. The following terms in this Agreement shall have the meanings set forth below: 
  
 1.1 “Change of Control” shall mean (i) the consummation of a merger, reorganization or other transaction or series of
related transactions following which the stockholders of the Company immediately prior to the transaction own less than 50% of the total voting power represented by the voting securities of the surviving entity (or its parent) outstanding
immediately after the transaction, and the directors serving on the Board immediately prior to such transaction fail to constitute a majority of the board of directors of the surviving entity (or its parent) immediately after such transaction; or
(ii) the consummation of the sale or disposition by the Company of all or substantially all of the Company’s assets. 
  
 1.2 “Cause” shall mean (i) the Executive’s material failure to perform the Executive’s assigned duties or
responsibilities (other than a material failure resulting exclusively from the Executive’s disability) or breach of any statutory duty the Executive owes to the Company after receipt of notice thereof from the Board or individual to whom the
Executive reports describing the Executive’s failure to perform such duties or responsibilities or breach and failure of the Executive to cure such failure or breach within thirty (30) days after such notice; (ii) the Executive’s
refusal or failure to follow the lawful and reasonable directions of the Board or individual to whom the Executive reports, which refusal or failure is not cured within thirty (30) days following delivery of a written notice of such conduct to
the Executive; (iii) the Executive engaging in any act of dishonesty, fraud or misrepresentation, which results or is intended to result in material harm to the Company’s business; (iv) the Executive’s violation of any federal or
state law or regulation applicable to the Company’s business, which results or is intended to result in material harm to the Company’s business; (v) the Executive’s breach of any confidentiality agreement, invention assignment
agreement or any other contract or agreement between the Executive and the Company (including but not limited to this Agreement); (vi) the Executive’s attempted commission of or participation in a fraud against the Company, or any material
act of dishonesty against the Company; or (vii) the Executive’s conviction of, or plea of nolo contendere to, any felony involving fraud, dishonesty or moral turpitude. 
  

 1 

 1.3 “Constructive Termination” shall mean the resignation of the Executive
due to the occurrence of any of the following without the Executive’s consent: 
  
 (a) ceasing to serve as a Chief Executive Officer of a publicly traded company; 
  
 (b) a material reduction in the Executive’s duties, position or responsibilities relative to the Executive’s duties, position or
responsibilities in effect immediately prior to the effective date of the Change of Control; provided, however, that a change in the Executive’s title or reporting relationships shall not in and of themselves (or collectively) constitute
a Constructive Termination; 
  
 (c) a material reduction by
the Company in the Executive’s annual base salary as in effect on the effective date of the Change of Control or as increased thereafter; provided, however, that Constructive Termination shall not be deemed to have occurred in the event
of a reduction in the Executive’s annual base salary that is pursuant to a salary reduction program affecting substantially all of the executive officers or employees of the Company and that does not adversely affect the Executive to a greater
extent than other similarly situated employees; or 
  
 (d)
a relocation of the Executive’s primary business office to a location more than fifty (50) miles from the location at which the Executive performed the Executive’s duties as of the effective date of the Change of Control, except
for required travel by the Executive with respect to the Company’s business to an extent substantially consistent with the Executive’s business travel obligations prior to the effective date of the Change of Control. 
  
 1.4 “Severance Benefits” shall mean
(a) Severance Payments and (b) acceleration, equal to the number of shares that would have vested if the Executive’s employment as CEO had continued for twelve (12) months after the employment termination date, of the shares
subject to the Executive’s stock option grants. 
  
 1.5
“Severance Payments” shall mean severance in the form of salary continuation for twelve (12) months at the base salary rate in effect as of the Executive’s employment termination date, subject to standard
payroll deductions and withholdings and paid on the Company’s normal payroll dates. 
  
 1.6 “Stock Awards” shall mean any and all stock awards granted to the Executive by the Company to acquire capital stock of the Company, whether granted prior to or after the date of this
Agreement (other than any stock awards granted to the Executive pursuant to a written stock award agreement which expressly provides that the terms and conditions of this Agreement shall not apply to such stock awards). 
  
 2. CHANGE OF CONTROL SEVERANCE
BENEFITS. 
  
 2.1 If one month prior to
or within thirteen (13) months after the effective date of a Change of Control, the Executive is either terminated by the Company without Cause or suffers a Constructive Termination; and, in either case, the Executive provides the Company with
a signed general release of all claims in substantially the form attached hereto as Exhibit A and allows this release to become effective, then the Executive shall be eligible for the following severance benefits: 
  

 2 

 (a) Severance Payments. The Company will pay the Executive severance in an amount equal to the
Executive’s annual base salary as in effect immediately prior to the Change of Control plus the Executive’s annual target bonus as in effect immediately prior to the Change of Control, the sum of which shall then be multiplied by 1. This
amount will be subject to standard payroll deductions and withholdings, and will be paid in semi-monthly installments beginning on the first payroll date after the Executive’s release of claims becomes effective, and continuing for 12 months
thereafter (the “Severance Period”). 
  
 (b) Health Insurance Payments. If, following the termination of Executive’s employment, the Executive timely elects continued group health insurance coverage under the federal COBRA law or similar state laws, if applicable, the
Company will reimburse the Executive’s COBRA premium costs to continue such coverage at the level in effect as of the Executive’s termination date through the earlier of the end of the Severance Period or the date the Executive
becomes eligible for group health insurance coverage through a new employer. If the Executive’s Severance Period extends beyond the time period for which the Executive is eligible for coverage under COBRA, then for that post-COBRA period of
time, the Company will reimburse the Executive for the premiums incurred by the Executive to obtain reasonably consistent coverage. The Executive must promptly notify the Company in writing if the Executive becomes eligible for group health
insurance coverage through a new employer during the Severance Period. 
  
 (c) Accelerated Vesting. All of the then remaining unvested shares of the capital stock of the Company subject to the Executive’s Stock Awards shall be deemed immediately vested and exercisable as of the date the
Executive’s employment is terminated. 
  
 2.2 The
Executive will not be eligible for any severance benefits under this Agreement if the Company (or its successor) terminates the Executive’s employment for Cause or if the Executive resigns for any reason other than a Constructive Termination.
Further, the Executive will not be eligible for severance benefits under this Agreement in the event that the Executive’s employment ends for any reason more than thirteen (13) months after the effective date of a Change of Control.

  
 3. OTHER SEVERANCE BENEFITS

  
 Provided that the Executive meets the condition set forth
in this paragraph, the Executive will be eligible to receive the Severance Benefits if,: (a) the Executive is terminated without Cause by the Company; or (b) the Executive resigns as CEO due solely to the hiring, or anticipated hiring, of
a specifically identified and viable CEO candidate. In order to be eligible for the Severance Benefits, the Executive must provide the Company with a signed general release of all claims in substantially the form attached hereto as Exhibit A and
allows this release to become effective. 
  
 4. ADJUSTMENTS

  
 4.1 Parachute Payments. If any payment or benefit
the Executive would receive in connection with a Change of Control from the Company or otherwise (“Payment”) would (i) constitute a “parachute payment” within the meaning of Section 280G of the Internal
Revenue 
  

 3 

 Code (the “Code”), and (ii) but for this sentence, be subject to the excise tax imposed by
Section 4999 of the Code (the “Excise Tax”), then such Payment shall be either (1) provided to the Executive in full, or (2) provided to the Executive as to such lesser extent that would result in no portion of
the Payment being subject to the Excise Tax, whichever of the foregoing amounts, when taking into account applicable federal, state, local and foreign income and employment taxes, the Excise Tax, and any other applicable taxes, results in the
receipt by the Executive, on an after-tax basis, of the greater amount of the Payment, notwithstanding that all or some portion of the Payment may be subject to the Excise Tax. If a reduction in the Payment is to be made as provided above,
reductions shall occur in the following order unless the Executive elects in writing a different order (provided, however, that such election shall be subject to Company approval if made on or after the date that triggers the Payment or a
portion thereof): (i) reduction of cash payments; (ii) cancellation of accelerated vesting of Stock Awards other than stock options; (iii) cancellation of accelerated vesting of Stock Awards that are stock options; and
(iv) reduction of other benefits paid to the Executive. If acceleration of vesting of Stock Awards is to be reduced, such acceleration of vesting shall be cancelled in the reverse order of date of grant of Executive’s Stock Awards
(i.e., the earliest granted Stock Awards cancelled last) unless the Executive elects in writing a different order for cancellation. 
  
 The accounting firm engaged by the Company for general audit purposes as of the day prior to the effective date of the Change of Control shall perform the
foregoing calculations. If the accounting firm so engaged by the Company is serving as accountant or auditor for the individual, entity or group effecting the Change of Control, the Company shall appoint a nationally recognized accounting firm to
make the determinations required hereunder. The Company shall bear all expenses with respect to the determinations by such accounting firm required to be made hereunder. Such accounting firm may make reasonable assumptions and approximations
concerning applicable taxes and may rely on reasonable, good faith interpretations concerning the application of the Code and other applicable legal authority. 
  

The accounting firm engaged to make the determinations hereunder shall provide its calculations, together with detailed supporting documentation, to
the Executive and the Company within fifteen (15) calendar days after the date on which the Executive’s right to a Payment is triggered (if requested at that time by the Executive or the Company) or such other time as requested by the
Executive or the Company. If the accounting firm determines that no Excise Tax is payable with respect to a Payment, it shall furnish the Executive and the Company with an opinion reasonably acceptable to the Executive that no Excise Tax will be
imposed with respect to such Payment. Any good faith determinations of the accounting firm made hereunder shall be final, binding and conclusive upon the Executive and the Company. 
  
 4.2 Application of Section 409A. In the event that the Company determines that any cash severance payment
benefit provided under Sections 2.1(a) or 3 or continued group health insurance coverage benefit provided under Section 2.1(b) fails to satisfy the distribution requirement of Section 409A(a)(2)(A) of the Code as a result of
Section 409A(a)(2)(B)(i) of the Code, the payment of such benefits shall be accelerated to the minimum extent necessary so that the benefit is not subject to the provisions of Section 409A(a)(1) of the Code. (The payment schedule as
revised after the application of the preceding sentence shall be referred to as the “Revised Payment Schedule.”) However, in the event the payment of benefits pursuant to the Revised Payment Schedule would be subject to
Section 409A(a)(1) of the Code, the payment of 
  

 4 

 such benefits shall not be paid pursuant to the original payment schedule or the Revised Payment Schedule and instead the
payment of such benefits shall be delayed to the minimum extent necessary so that such benefits are not subject to the provisions of Section 409A(a)(1) of the Code. The Board may attach conditions to or adjust the amounts paid pursuant to this
Section 4.2 to preserve, as closely as possible, the economic consequences that would have applied in the absence of this Section 4.2; provided, however, that no such condition or adjustment shall result in the payments being
subject to Section 409A(a)(1) of the Code. 
  
 5. GENERAL
PROVISIONS. 
  
 5.1 Prior Agreements.
The Executive acknowledges and agrees any prior agreement between the Executive and the Company providing for or relating to severance benefits, including, but not limited to, Engagement Letter dated January 1, 2002, the Contract Extension
dated August 7, 2003 and the letter agreement dated March 4, 2004, are hereby expressly superseded and replaced in their entirety by this Agreement and shall have no further force or effect. 
  
 5.2 At Will Employment. Nothing in this Agreement alters the
Executive’s at-will employment status. Either the Executive or the Company may terminate the Executive’s employment relationship at any time, with or without cause or advance notice. In particular, nothing expressed or implied in this
Agreement will create any right or duty on the part of the Company or the Executive to have the Executive remain in the employment of the Company or any subsidiary prior to or following any Change of Control. 
  
 5.3 Successors and Binding Agreement. This Agreement will be binding
upon and inure to the benefit of the Company and any successor to the Company, including without limitation any persons acquiring directly or indirectly all or substantially all of the business or assets of the Company whether or not through a
Change of Control (and such successor shall thereafter be deemed the “Company” for the purposes of this Agreement). This Agreement will inure to the benefit of and be enforceable by the Executive’s personal or legal representatives,
executors, administrators, successors, heirs, distributees and legatees. 
  
 5.4 Amendments. No provision of the Agreement may be amended, modified or waived unless such amendment, modification or waiver shall be agreed to in writing and signed by the Executive and a duly authorized
officer of the Company. 
  
 5.5 Severability. If any
provision of the Agreement shall be determined to be invalid or unenforceable by a court of competent jurisdiction, the remaining provisions of the Agreement shall be unaffected thereby and shall remain in full force and effect to the fullest extent
permitted by law. 
  
 5.6 Notices. Any notice or other
communication required or permitted under the Agreement shall be in writing and shall be deemed to have been duly given when delivered by hand, electronic transmission (with a copy following by hand or by overnight courier), by registered or
certified mail, postage prepaid, return receipt requested or by overnight courier addressed to the other party. All notices shall be addressed as follows, or to such other address or addresses as may be substituted by notice in writing: 

 

			
	 To the Company:
 Conor Medsystems, Inc.
 1003 Hamilton Court
 Menlo Park, CA 94025
	  	 To the Executive:
 Frank Litvack, M.D.
 c/o Conor Medsystems, Inc.
 1003 Hamilton Court
 Menlo Park, CA 94025

  

 5 

 5.7 Governing Law. The Agreement shall be construed, interpreted and governed in accordance with
the laws of the State of California, without reference to rules relating to conflicts of law. 
  
 5.8 Independent Counsel. The Executive acknowledges that this Agreement has been prepared on behalf of the Company by Cooley Godward LLP, counsel to the Company and that Cooley Godward LLP does not represent,
and is not acting on behalf of, the Executive. The Executive has been provided with an opportunity to consult with the Executive’s own counsel with respect to this Agreement. The Executive understands that the Company does not make any
representation or warranty as to the tax treatment of the Executive’s Stock Awards. 
  
 5.9 Counterparts. This Agreement may be executed in one or more counterparts, each of which shall be deemed to be an original but all of which together will constitute one and the same agreement. 
  

 6 

 IN WITNESS WHEREOF, the parties have executed this
Executive Change of Control Severance Agreement as of the date first written above. 
  

									
	CONOR MEDSYSTEMS, INC.	 	 	 	EXECUTIVE
					
	 By:
	 	 /s/ Michael Boennighausen

	 	 	 	By:	 	 /s/ Frank Litvack 

	Name:	 	Michael Boennighausen	 	 	 	Print Name:	 	Frank Litvack, M.D.
	Title:	 	Chief Financial Officer	 	 	 	 	 	 

  

 7 

 EXHIBIT A 
  
 RELEASE AGREEMENT 
  
 Reference is made to that certain Chief Executive Change of Control and Severance Agreement by and between Conor Medsystems, Inc. and myself dated
September 27, 2005 (the “Agreement”). 
  
 I hereby
confirm my obligations under the Company’s proprietary information and inventions agreement. 
  
 I acknowledge that I have read and understand Section 1542 of the California Civil Code which reads as follows: “A general release does not
extend to claims which the creditor does not know or suspect to exist in his favor at the time of executing the release, which if known by him must have materially affected his settlement with the debtor.” I hereby expressly waive and
relinquish all rights and benefits under that section and any law of any jurisdiction of similar effect with respect to my release of any claims I may have against the Company. 
  
 In exchange for the benefits I am receiving under the Agreement, I hereby generally and completely release the Company and
its directors, officers, employees, shareholders, partners, agents, attorneys, predecessors, successors, parent and subsidiary entities, insurers, affiliates, and assigns from any and all claims, liabilities and obligations, both known and unknown,
that arise out of or are in any way related to events, acts, conduct, or omissions occurring prior to my signing this Agreement. This general release includes, but is not limited to: (1) all claims arising out of or in any way related to my
employment with the Company or the termination of that employment; (2) all claims related to my compensation or benefits from the Company, including salary, bonuses, commissions, vacation pay, expense reimbursements, severance pay, fringe
benefits, stock, stock options, or any other ownership interests in the Company; (3) all claims for breach of contract, wrongful termination, and breach of the implied covenant of good faith and fair dealing; (4) all tort claims, including
claims for fraud, defamation, emotional distress, and discharge in violation of public policy; and (5) all federal, state, and local statutory claims, including claims for discrimination, harassment, retaliation, attorneys’ fees, or other
claims arising under the federal Civil Rights Act of 1964 (as amended), the federal Americans with Disabilities Act of 1990, the federal Age Discrimination in Employment Act of 1967 (as amended) (“ADEA”), and the California Fair Employment
and Housing Act (as amended). 
  
 I acknowledge that I am
knowingly and voluntarily waiving and releasing any rights I may have under ADEA. I also acknowledge that the consideration given under the Plan for the waiver and release in the preceding paragraph hereof is in addition to anything of value to
which I was already entitled. I further acknowledge that I have been advised by this writing, as required by the ADEA, that: (A) my waiver and release do not apply to any rights or claims that may arise on or after the date I execute this
Release Agreement; (B) I have the right to consult with an attorney prior to executing this Release Agreement; (C) I have twenty-one (21) days to consider this Release Agreement (although I may choose to voluntarily execute it
earlier); (D) I have seven (7) days following my execution of this Release Agreement to revoke it; and (E) this 
  

 8 

 Release Agreement shall not be effective until the date upon which the revocation period has expired, which shall be the
eighth (8th) day after I execute this Release Agreement. 
  

			
	EMPLOYEE
		
	Name:	 	  

	Date:	 	  

  

 9

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00091-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00091-of-00352.parquet"}]]